¡¡ Registration
  Pre-Registration
  Registration
  Hotel Info
  Tech Tour
  For Accompanies
  Food Preferences
 ¡¡ IDDST 2008
  General Information
  Tracking Record
  Organizers & SAB
  Agenda
  Keynote Lectures
  Pre/Post-Conference
  Scientific Program
  Key Dates
  About the Venue
  Online Broadcasting Tool
 ¡¡ For Speakers
  Why Speak?
  Oral Presentations
  Abstracts & Biography
¡¡ For Exhibitors
  Exhibitors
  Media Partners
  Posters
  Job Posting
 ¡¡ For Sponsors
  Who Should Sponsor?
  Sponsorship Options
 ¡¡ For Attendees
  Group Participants
  Individuals
  Invitation and Visa
 ¡¡ Business Development
  Innovators
  Investors
  Market Expansion
  Advertisement
  Outsourcing
 ¡¡ Beijing and Xian
  Olympic City-Beijing
  Culture City-X'ian
  Transportation
  Weather
  Photo Gallery
  ¡¡Additional Information
  Call for Co-Organizers
  Help & FQA
  Send Feedback
 ¡¡ BIT's upcoming events
 
 
2008 iBio
(May 18-22, 2008,Hangzhou,China)
CEMD-2008
( Oct.22-28, 2008, Beijing & Xi'an, China )
WCV 2008
( Dec.1-5, 2008, Guangzhou, China)
WCG 2008
(Dec. 5-7, 2008, Guangzhou, China)
 
 
Scientific Program

    Congress Dates : October 18-22, 2008     Beijing Loong Palace Hotel & Resort, Beijing
    Exhibition Dates : October 19-21, 2008


08 IDDST Tentative Program

Time: October 18-22, 2008

Venue: Loong Palace Hotel, Beijing, China

 

 

Pre-Conference Summit :
 

Oct.17, 2008

13:30-17:30

Workshop 1: How to File IND with China SFDA
Workshop 2: What Policy Privilege for Foreign Inventor to Develop Biopharmaceuticals in China
Workshop 3: Opportunities and Challenges upon Off-Patent Blockbusters

Oct.22, 2008

8:30-11:30

Workshop 4: New Paradigm of Alliance /Collaborative Drug Discovery with Academia in China
Workshop 5: How to Meet FDA Requirement by Performing Effective Clinical Trials for INDs in China

Workshop 6: Botanical Drugs: Production, Analyses and FDA Regulations

Dr. J. Briggs, Director, National Center for Complementary and Alternative Medicine, NIH, USA  

Objective: Outlining the scientific, clinical and regulatory steps involved in transformation of herbal medicines to safe and effective botanical drugs.

Topics:

1. Data collection on efficacy and safety, to show safe human use.

Documentation of clinical data based on traditional healers' practice, documentation of the quality (chemical and biological characterization) of the product used.

2. Good agricultural and collection practices, and Good manufacturing practices, to ensure batch to batch consistency.

3. Chemical characterization of complex mixture used in traditional medicine

4. Characterization by biological tests

5. Pharmacological studies.

6. Toxicological studies.

7. Clinical studies

8. Collaborations (as collection of plants and transport may be an issue and also some of the activity may be lost)
- Scientific and clinical collaborations

- environmental consideration.

9. Patent and marketing exclusivities

10. FDA ¨C preparation of application using ICH guidelines, preparation of eCTD.

 
The Main Scientific Program will take place from 09:00-17:00 during October 18-22, 2008. 600+ Research and Industrial Presentations divided into six tracks with sixty-eight sessions in total. The ten sessions offered will run concurrently per half day.

Click following session number for detailed program:

 

Morning of October 19


Plenary Lectures

-- From Novel Targets to Billion Dollar Molecules

Special Symposium Sponsored by ACS-Medichem Division



Afternoon of October 18, Afternoon of October 19


Track 1: Applicable and Frontier Scientific Methodologies and Models

-Great Thoughts for Deciphering Human Disorders

For Detail Track Info: Click here, Session 1-20


Morning of October 20


Track 2: How Advanced Medicinal Chemistry Help Your prototype molecules to Blockbusters

-Listen to Successful Case Story from Big Phmarmas and Enjoy the Voice of ACS Medichem

For Detail Track Info: Click here, Session 21-25



Morning of October 20


Track 3: Translational Cutting-Edge Technologies

-Speeding Discovery Process with Niches

For Detail Track Info:
Click here, Session 26-35



Morning of October 20, Afternoon of October 21, Morning of October 22


Track 4: Therapeutics Development for Major and Rare Diseases

-Delivering Promises for Future Drugs

For Detail Track Info: Click here, Session 36-55



Morning of October 22


Track 5:: Nature Product Based Drug Discovery

-Mining 5000 Year Nature Pool

For Detail Track Info: Click here, Session 56-60



Morning of October 22


Track 6: Drug R & D Partnering in China

-Integrating Resources and Talents from the East To Slow Your Money Burning Rate Increase pipeline successful percentage

For Detail Track Info: Click here, Session 61-65

 

 
 
Track 1: Drug Discovery Sciences ¡øTOP
-Great Thoughts for Deciphering Human Disorders
 

Time

Sessions

Oct.18, 2008
Saturday
13:30-17:30

Session 1: ¡°-Omics¡±, Molecular Genetics to System Biology and Drug Discovery

Session Chair:

Dr. Christian Pasquali, Professor, Geneva Research Center, Merck Serono International S.A., Switzerland

Co-Chair:

Call for Co-Host
13:30-13:55

Title: HPLC-Chip/MS: a New Powerful Analytical Technology

Dr.
Rudolf Grimm, Market Development Manager, Agilent Technologies Inc., USA

13:55-14:20

Title: TBD

Dr. Ira L. Goldknopf,
Director of Proteomics, Power3 Medical Products, Inc., USA

14:20-14:45

Title: Importance of Physical Prediction in Peptide/Protein Fractionation for the Cleanup of Bioinformatics Database in Proteomics

Dr. Joel Rossier, CSO, DiagnoSwiss S.A., Switzerland

14:45-15:10

Title: The Use of Support Vector Machine (SVM) Technology to Develop Molecular Diagnostic Tests

Dr. Stephen D. Barnhill,
Chairman and Chief Executive Officer, Health Discovery Corporation, USA

15:10-15:25 Coffee Break
15:25-15:50

Title: A Chemical Proteomics Approach to Phosphatidylinositol 3-Kinase Signaling in Macrophages

Dr. Christian Pasquali,
Professor, Geneva Research Center, Merck Serono International S.A., Switzerland

15:50-16:15 Title: Computational Genetics: Toward Understanding Our Drugs and Diseases

Dr. Guochun Liao, Group Leader, Roche Pharmaceuticals, USA
16:15-16:40

Speech Opportunity is Available

16:40-17:05

Title: Nutrigenomic and Immunosenescence

Dr. Eugenio Mocchegiani,
Immunology Centre, (Section: Nutrition, Immunity and Ageing). Res. Dept. Italian National Research Centres on Ageing (I.N.R.C.A), Italy

17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 2: Regenerative Medicine and Drug Discovery

Session Chair:

Dr. Christophe Labie, Head, Neurobiology Group, Sanofi-aventis, Inc., France

Co-Chair:

Call for Co-Host
13:30-13:55

Title: Novel Polymeric Artificial Cells for Nanomedicine and Regenerative Medicine

Dr. Thomas Ming Swi Chang,
Director, Artificial Cells & Organs Research Centre, McGill University, Canada

13:55-14:20 Speech Opportunity is Available
14:20-14:45

Title: Stem cells and Regenerative Medicine

Dr. Michele De Luca,
Full Professor of Biochemistry and Director, Centre for Regenerative Medicine, Department of Biomedical Sciences, University of Modena and Reggio Emilia, Italy

14:45-15:10

Speech Opportunity is Available

15:10-15:25 Coffee Break
15:25-15:50

Title: TBD

Dr. Christophe Labie, Head, Neurobiology Group, Sanofi-aventis, Inc., France

15:50-16:15

Title: TBD

Dr. Masaaki Kitada, Professor, Department of Anatomy and Neurobiology, Kyoto University Graduate School of Medicine, Japan

16:15-16:40 Speech Opportunity is Available
16:40-17:05 Speech Opportunity is Available
17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 3: Molecular/Cell Biology and Drug Discovery

Session Chair:

Dr. Michael R. Briggs, Senior Director and Head of Cell & Molecular Biology, Vertex Pharmaceuticals, Inc., USA

Co-Chair:

Dr. Jingwen Liu, Principal Investigator, VA Palo Alto Health Care System, USA
13:30-13:55

Title: Finding Novel Cancer Drugs that Address Unmet Medical Needs

Dr. Michael R. Briggs,
Senior Director and Head of Cell & Molecular Biology, Vertex Pharmaceuticals, Inc., USA

13:55-14:20 Speech Opportunity is Available
14:20-14:45 Title: TBD

Dr. Huichuan Sun,
Porfessor, Liver Cancer Institute of Fudan University, China
14:45-15:10

Title: Peptide Inhibitors of Metastasis in Liver Cancer

Dr. Yinkun Liu,
Deputy Director, Liver Cancer Institute of Fudan University, China

15:10-15:25 Coffee Break
15:25-15:50

Title: The Identifications of the Molecular Targets for Berberine Mediated Cholesterol Reduction in Plasma and in Liver

Dr. Jingwen Liu,
Principal Investigator, VA Palo Alto Health Care System, USA

15:50-16:15

Title: TBD

Dr. Ilho Ha, Director, BioScience Center Hanwha Chemical R&D Institute Hanwha Chemical Co., Korea

16:15-16:40 Speech Opportunity is Available
16:40-17:05

Title: Wisdom: Grid Computing Enabled Identification of Active Molecules against Targets Implicated in Malaria

Dr. Vincent Breton,
Research Associate, CNRS-IN2P3 Laboratory, France

17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 4: Immunology and Drug Discovery

Session Chair:

Dr. Prakash Nagarkatti, Associate Dean for Basic Science, University of South Carolina School of Medicine, USA

Co-Chair:

Call for Co-Host
13:30-13:55

Title: Synthesis and Assembly Of Human Papillomavirus Type 16 L 1 Virus-like Particles

Dr. Robin L. Thurmond,
Project Leader, Johnson & Johnson Pharmaceutical Research, USA

13:55-14:20 Speech Opportunity is Available!
14:20-14:45 Speech Opportunity is Available!
14:45-15:10

Title: The Interleukin-6 Inflammation Pathway from Cholesterol to Aging ¨C Role of Statins, Bisphosphonates and Plant Polyphenols in Aging and Age-related Diseases

Dr. Sota Omoigui, Director, Division of Inflammation and Pain Medicine, L.A Pain Clinic, USA

15:10-15:25 Coffee Break
15:25-15:50

Title: Use of Cannabinoids as Novel Anti-inflammatory Drugs through Potential Targeting of CB2 Receptors

Dr. Prakash Nagarkatti,
Associate Dean for Basic Sciences, University of South Carolina School of Medicine, USA

15:50-16:15

Title: Targeting the Cannabinoid System as a Novel Therapeutic Modality to Treat Cancers of the Immune System

Dr. Mitzi Nagarkatti,
Deputy Director of Cancer, University of South Carolina, USA

16:15-16:40

Title: Novel Aryl-thiazolidones and Their Complexes with Ruthenium: Endowed with Anti- trypanosoma Cruzi Activity

Dr. Ana Cristina Lima Leite,
Professor and Director, Federal University of Pernambuco, Brazil

16:40-17:05 Speech Opportunity is Available
17:05-17:30

Title: Neural Mechanism Involved in Chagas Cardiomyooathy: From Neurogenic to Immunogenic Trophic Theories

Dr. Rafael Bonfante-Cabarcas,
Director of Biomedical Science PhD Program, Department of Functional Science, School of Medicine, Universidad Cent occidental "Lisandro Alvarado", Venezuela

17:30-17:55

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 5: Oncology and Drug Discovery

Session Chair:

Call for Host

Co-Chair:

Dr. M. Asif Chaudry, University Department of Surgery Royal Free & University College London, UK

13:30-13:55

Title: Tumor-Selective Anticancer Drugs from Amphiphilic Organophosphazenes

Dr. Youn Soo Sohn,
Distinguished Professor, Department of Chemistry, Division of Nano Science, Ewha Womans University, Korea

13:55-14:20

Title: Fragment Based Drug Discovery Using Rational Design

Dr. Harren Jhoti,
Chief Executive Officer, Astex Therapeutics, Cambridge, UK

14:20-14:45

Title: TBD

Dr. M Asif Chaudry,
University Department of Surgery Royal Free & University College London, UK

14:45-15:10

Title: Membrane Transporters in Oncology Drug Discovery

Dr. Bal¨¢zs Sarkadi, Professor, Head of the Membrane Research Group, Hungarian Academy of Sciences, Hungary

15:10-15:25 Coffee Break
15:25-15:50

Title: TBD

Dr. Hwei-Ru Tsou,
Principal Research Scientist, Wyeth Research, USA

15:50-16:15

Title: Prodigiosin, a New Apoptotic Agent with Anticancer Properties

Dr. Ricardo P¨¦rez-Tom¨¢s,
Professor, School of Medicine, University of Barcelona, Spain

16:15-16:40

Title: Targeting Multidrug Resistant Cancer

Dr. Gergely Szak¨¢cs,
Professor, Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest, Hungary

16:40-17:05

Title: The SV40 Large T Antigen-p53 Complexes Bind and Activate the Insulin-like Growth Factor-I Promoter Stimulating Cell Growth

Dr. Michele Carbone,
Professor and Chairman, Department of Pathology, John A. Burns School of Medicine; Director Thoracic Oncology Program, Cancer Research Center, University of Hawaii, USA

17:05-17:30

Speech Opportunity is Available

17:30-17:55

Title: PET Microdosing in Anticancer Drug Development

Dr. Kirsten Bouchelouche,
Place City Odense University Hospital, Denmark

17:55-18:15

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 6: Microbiology, Virology and Drug Discovery

Session Chair:

Call for Host

Co-Chair:

Call for Co-Host
13:30-13:55 Title: Discovering Enteric Dialysis ¨C The Gut Based Uremia Therapy for Chronic Kidney Failure Applications

Dr. N. Ranganthan, Interim CEO, Kibow Biotech, USA
13:55-14:20

Title: TBD

Dr. Thomas Baumert,
Director, University Louis Pasteur, France

14:20-14:45

Title: Structure Guided Design, Synthesis and Characterization of Inhibitors of the Bacterial enoyl-ACP Reductase FabI

Dr. Judd Berman,
CSO, Dalton Medicinal Chemistry, Inc., USA

14:45-15:10

Title: TBD

Dr. Orig¨¨ne Nyanguile,
Principal Scientist, Tibotec BVBA, Belgium

15:10-15:25 Coffee Break
15:25-15:50

Title: TBD

Dr. Michael Bukrinsky,
Professor and Vice Chair, The George Washington University, USA

15:50-16:15 Speech Opportunity is Available!
16:15-16:40

Title: TBD

Dr. Ming Q Wei,
Editorial Board, University of Queensland, Australia

16:40-17:05

Title: TBD

Dr. Mia Levite, Senior Scientist/Lecturer, The Weizmann Institute of Science, Israel

17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 7: Neurology and Drug Discovery

Session Chair:

Call for Host

Co-Chair:

Call for Co-Host
13:30-13:55

Title: TBD

Dr. Michael A. Palladino, Jr.,
Senior Vice President, Chief Technology Officer and Scientific Co-founder, Neuropharm, Inc., USA

13:55-14:20

Title: Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases): What can be Learned by Studies on Cu(II)-peptide Complexes

Dr. Gianni Valensin,
Professor, Director of the NMR Centre of the University of Siena, Italy

14:20-14:45

Title: TCA Cycle May Play an Important Role for Protection Against Epileptic Seizures

Dr. Hiro-aki Yamamoto,
Associate Professor, University of Tsukuba, Japan

14:45-15:10

Title: The Neurobiological Bases of AED Resistance

Dr. Lazarowski Alberto,
Clinical Biochemistry Department, PlaceType School PlaceName of Pharmacy and Biochemistry, PlaceType University of PlaceName Buenos Aires (UBA), Argentina

15:10-15:25 Coffee Break
15:25-15:50

Title: TBD

Dr. Sabina Janciauskiene,
Lund Universit, University Hospital, Sweden

15:50-16:15

Title: Mechanism-based Development of Memantine as A Therapeutic Agent in Treating Alzheimer's Disease and other Neurologic Disorders

Dr. HS Vincent Chen,
Assistant Professor, University of California, USA

16:15-16:40

Title: Serotonin 5-HT 1A Receptors : How New Mechanisms are Driving Innovation and Drug Discovery

Dr. Adrian Newman-Tancredi,
Director, Neurobiology 2 Division, Institut de Recherche Pierre Fabre, France

16:40-17:05

Title: TBD

Dr. Jorge Ju¨¢rez, Professor, Universidad de Guadalajara, M¨¦xico

17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 8: Hepatology and Drug Discovery

Session Chair:

Call for Host

Co-Chair:

Call for Co-Host
13:30-13:55 Call for Keynote Speaker
13:55-14:20

Title: Chemoembolizattion of Hepatic Neoplasm with Drug-eluting Microspheres

Dr. T. Gregory Walker,
Section of Cardiovascular Imaging and Intervention, Massachusetts General Hospital, USA

14:20-14:45 Speech Opportunity is Available
14:45-15:10

Title: An Old Drug for a New Therapeutic Frontier: ACE Inhibitors in the Battle against Liver Fibrosis

Dr. Igino Rigato,
Senior Investigator, AREA Science Park and University Hospital of Trieste, Italy

15:10-15:25 Coffee Break
15:25-15:50

Title: Drug Structure- Hepatic Pharmacokinetic Relationships in Normal and Diseased Livers

Dr. Michael S Roberts,
University of Queensland, Australia

15:50-16:15 Speech Opportunity is Available
16:15-16:40 Speech Opportunity is Available
16:40-17:05

Title: The 3D Cell Models and Supporting Technologies for Hepatotoxicity Testing of Drugs

Dr. Hanry Yu,
Associate Professor, National University of Singapore, Singapore

17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 9: Endocrinology and Drug Discovery

Session Chair:

Call for Host

Co-Chair:

Call for Co-Host
13:30-13:55 Call for Keynote Speaker
13:55-14:20

Title: TBD in Field of Diabetes or Kinase Inhibitor

Dr. Tang Peng Cho, Chief Scientific Officer, Shanghai Hengrui Pharmaceuticals, China

14:20-14:45

Title: Progress and Limitation of the Andidiabetic Drug Treatment

Dr. Guntram Schernthaner,
Professor andHead, Rudolfstiftung Hospital-Vienna, Austria

14:45-15:10 Speech Opportunity is Available
15:10-15:25 Coffee Break
15:25-15:50 Speech Opportunity is Available
15:50-16:15

Title: Investigating Effects of Anesthetics on Bbeta Amyloid Peptide Accumulation and Aggregation, the Key Pathogenic Event in Alzheimer Disease

Dr. Vincenzo Fodale,
Aggregate Professor, University of Messina, Italy

16:15-16:40 Speech Opportunity is Available
16:40-17:05 Speech Opportunity is Available
17:05-17:30

Panel Discussion

3-5 topics will be proposed by Session Chair

Oct.18, 2008
Saturday
13:30-17:30

Session 10: Pharmacology, Toxicology and Pathology in Drug Discovery

Session Chair:

Dr. Tian Yang, Research Leader, Roche Pharmaceuticals, USA